13 May , 2024

News Release

EFPIA Japan

EFPIA Japan Calls for Applications for the 7th PASE AWARD
to Support Patient Organizations
Grants to be awarded to up to five organizationsfor action plans to improve patients’ health and quality of life

The European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan;
Chair: Takahiko Iwaya) is pleased to announce that it has started to call for entry to the 7th PASE
AWARD (Patient Advocacy Support by EFPIA Japan) today. EFPIA Japan initiated the PASE
AWARD program in 2017 as a means to further improve the healthcare environment for patientsby encouraging patient advocacy activities in Japan and having their voices appropriatelyreflected in the healthcare system.
This year's award theme is patient advocacy for improving patient health and quality of life. The
selection process consists of a primary document review and a final presentation to the external
jury and EFPIA Japan's directors. Grants will be awarded to up to five organizations.
Last year, EFPIA Japan expanded its program to include unincorporated patient groups, resulting
in receiving insightful proposals from diverse organizations. In recognition of this variety ofapplicants, this year's award grant will be capped at 50% of each organization’s annual budget ofrevenue and expenses with a maximum of 500,000 yen and a minimum of 150,000 yen to ensurethat no organization is excluded from this opportunity because of its organization size.
Over the last six years, a total of 106 organizations submitted a wide range of activity plans
through the PASE AWARD, and EFPIA Japan provided a total of 8.4 million yen in grants to 12
organizations for the Grand Prize and 18 organizations for the Honour Award. Please see here aseparate document for the past winning programs. This year's entry will close on July 5. EFPIA
Japan looks forward to applications from many organizations.

The 7th PASE AWARD – Overview of Application Guidelines
Accepting entries of organization activity plans in line with the award themeAward theme:
Patient advocacy for improving patient health and quality of life
1. Qualification Requirements(1) Patient organization working for patients in Japan(2) Have a specific plan for activities utilizing the grant (including how the grant will be used)(3) Able to submit “information required for application” described in the application
guidelines(4) Have the willingness to disseminate the results of activities utilizing the grant (permission
to post on EFPIA Japan's website, notification and reporting on the patient advocacy
group's own websites and through other channels)(5) Confirm by bylaws, articles of incorporation, and list of directors that the organization is
not led by a healthcare professional
2. Period of conducting activities(1) Conduct activities using the grant from the day of receiving the award to September 15,2025(2) Submit an activity report (two A4 pages) to the EFPIA Japan Secretariat by September
30, 2025.
3. Requirements of the award-winning organizations
Attend the PASE AWARD ceremony scheduled in October 2024 in Tokyo. (There may bemedia interviews.)
4. About grants
The grants will be provided depending on the budget of each organization: up to 50% of an
entrant's budget of revenues and expenses for the current year, with the maximum of
500,000 yen (if 50% of budget is 500,000 yen or more) and the minimum of 150,000 yen (if50% of budget is 150,000 yen or less).
5. Where to find entry rules and application method
Read the full entry rules (link below) carefully, fill out the activity plan application form, andsend it along with supporting materials in PDF by email to EFPIA Japan PASE AWARD
Secretariat (pase-award@cocoknots.co.jp) by July 5, 2024.
The PASE AWARD application requirements can be found on the PASE AWARD page of theEFPIA website. http://www.efpia.jp/pase/index.html

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan

About the EFPIA Japan Patient Organization Support Program “PASE”
EFPIA Japan works with patients to support opportunities and activities that address patientneeds and policy proposals. The PASE (Patient Advocacy Support by EFPIA Japan) AWARD
was created by EFPIA Japan in 2017 as a means to more directly carry out its patient-centricmission to support patient organizations and promote the development of patient advocacy inJapan.
In the 6th PASE AWARD held last year, we provided a total of 1.8 million yen to 3 organizations
for the Grand Prize and 2 organizations for the Honour Award, which were selected from the 20organizations that applied.
Please see the link for more information.
http://efpia.jp/link/231003_jp_press-release_pase-award_vfinal.pdf
About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceuticalcompanies operating in Japan. In 2022, combined sales from the member companies accounted
for roughly 31% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents thebiopharmaceutical industry operating in Europe. Through its direct membership of 37 nationalassociations, 40 leading pharmaceutical companies, and a growing number of small and medium
sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables
our members to innovate, discover, develop, and deliver new therapies and vaccines for people
across Europe, as well as contribute to the European economy.

Contact:
Hitoshi Fujita

Naomi Sakai

EFPIA Japan Communications Committee

In charge of PASE, EFPIA Japan Patient〒105-6333

Committee

1-23-1 Toranomon, Minato-ku, Tokyo〒141-6017

Toranomon Hills Mori Tower

2-1-1 Osaki, Shinagawa-ku, Tokyo

Novartis Pharma K.K.

ThinkPark Tower

TEL: 090‐9837‐4326

Nippon Boehringer Ingelheim Co., Ltd.

Mail: hitoshi.fujita@novartis.com

TEL: 03-6417-2489
Mail: naomi.sakai@boehringer-ingelheim.com

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan